Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease
Stock Information for OTC Markets Group Inc - Class A
Loading
Please wait while we load your information from QuoteMedia.